As expected, recent studies have reported that the combination of a glutamine antagonist and anti-PD-1 therapy had a more obvious anti-tumor effect than did the anti-PD-1 therapy alone, and did not cause immune cell failure (Leone et al., 2019). The gene discussed is PDCD1; the disease is neoplasm.